



GAU 1647
PATENT APPLICATION
File No. 99-16



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Julia E. Parrish, Scott R. Presnell, Cindy A. Sprecher,
Donald C. Foster, Richard D. Holly, Jane A. Gross,
Janet V. Johnston, Andrew J. Nelson, Stacey R. Dillon,
Angela K. Hammond

Serial No.: 09/522,217

Group Art Unit: 1647

Filed: March 9, 2000

Examiner: Seharaseyon, J.

For: NOVEL CYTOKINE ZALPHA11 LIGAND

AMENDMENT FEE TRANSMITTAL

Commissioner for Patents
Washington, DC 20231

Sir:

Transmitted herewith is an Amendment for the above-mentioned application. The fee required to be filed with the accompanying amendment has been calculated as shown below:

CLAIMS AS AMENDED

	Claims Remaining After Amendment	Highest No. Covered by Previous Payments	Present Extra	Extra Rate	Fee
Total	26	-43	0	\$9.00	\$000.00
Independent	14	-16	0	\$40.00	\$000.00
1st Presentation of Multiple Dependent Claim				\$135.00	\$000.00
				Total	\$000.00

Applicants claim small entity status. Please charge any required fee to ZymoGenetics, Inc., Deposit Account No. 26-0290. A duplicate of this sheet is enclosed.

Respectfully submitted,

Deborah A. Sawislak
Registration No. 37,438

A



PATENT APPLICATION

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231.

February 8, 2001

Date

Deborah A. Sawislak

Deborah A. Sawislak

RECEIVED
U.S. PATENT AND TRADEMARK OFFICE
FEB 17 2001

6/2
1/9/01
2/17/01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Julia E. Parrish, Scott R. Presnell, Cindy A. Sprecher, Donald C. Foster, Richard D. Holly, Jane A. Gross, Janet V. Johnston, Andrew J. Nelson, Stacey R. Dillon, Angela K. Hammond

Serial No.: 09/522,217

Filed: March 9, 2000

For: NOVEL CYTOKINE ZALPHA11 LIGAND

Examiner: Seharaseyon, J.

Art Unit: 1647

Docket No.: 99-16

Date: February 8, 2001

Commissioner for Patents
Washington, D.C. 20231

Response to Restriction Requirement and Preliminary Amendment

Sir:

02/20/2001 GTRAMMEL 00000001 260290 09522217
01 FC:103 254.00 CH
02 FC:102 720.00 CH
In response to the Restriction Requirement dated January 8, 2001, please amend the above-identified patent application as follows:

In the Specification:

On page 26, line 27, please delete -33--, and insert therefore "32".

On page 41, line 1, please delete -33--, and insert therefore "32".

On page 100, line 28, please delete -fixed--, and insert therefore "fixed".

In the Claims:

6. (amended) An isolated polypeptide comprising a sequence of amino acid residues as shown in SEQ ID NO: 2 from residue 32 (Gln) to residue 162 (Ser) [or as shown in SEQ ID NO: 56 (mouse) from residue 23 (Gln) to residue 146 (Ser)].

7. (amended) The isolated polypeptide of claim 6, wherein the sequence of amino acid residues as shown in SEQ ID NO: 2 is residue 1 (Met) to residue